Autres langues Alvotech

Actions

ALVO

LU2458332611

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:07:22 09/09/2026			Varia. 5j.	Varia. 1 janv.
5,200 ^USD	-2,26%		+1,53%	+3,70%

31/08	L'action Alvotech progresse après l'acceptation par la FDA de la demande de licence biologique pour l'AVT80	MT
31/08	La FDA accepte d'examiner la demande d'Alvotech pour son biosimilaire de l'Entyvio	MT

Autres langues

07/09	Takeda Files BPCIA Suit Against Alvotech For Vedolizumab Biosimilar
02/09	Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars
31/08	Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80
31/08	Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review
31/08	Alvotech Says FDA Accepted Biologics License Application for AVT80
31/08	Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
31/08	Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80 Biosimilar to Entyvio
27/08	Alvotech to present at upcoming investor conferences in September
24/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says
24/08	Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets
24/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
24/08	Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal
21/08	Alvotech And Lotus Pharmaceutical Enter Licensing And Commercialization Agreement For Proposed Biosimilars To Durvalumab And Emicizumab In The United States And Selected Asian Markets
21/08	Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets
21/08	Alvotech Signs Licensing Deal With Lotus Pharmaceutical for Proposed Biosimilars
21/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
20/08	Alvotech Provides Earnings Guidance for the Full Year 2026
19/08	Alvotech Reports Earnings Results for the Half Year Ended June 30, 2026
19/08	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
10/08	Alvotech to Report Financial Results for H1 2026
30/07	Alvotech Announces Successful Closure Of U.S Food and Drug Administration Inspection Of Manufacturing Facility
29/07	Alvotech Shares Rise After Wrapping FDA Facility Inspection
29/07	US FDA Closes Inspection of Alvotech's Manufacturing Facility in Iceland
29/07	Alvotech announces successful closure of FDA inspection of manufacturing facility
29/07	Alvotech announces successful closure of FDA inspection of manufacturing facility